Zylö Therapeutics
Zylö Therapeutics is dedicated to enhancing drug delivery through innovative encapsulation technologies, specifically utilizing their proprietary Z-pods®. Their mission is to improve product performance across various market segments by increasing bioavailability, stability, and targeted delivery of therapeutic compounds.
Zylö Therapeutics
105A Ben Hamby Rd., Greenville, SC 29615
What We Do
Highly engineered amorphous silica particles designed to encapsulate compounds and improve product performance in a wide range of market segments. Z-pods® can be adapted to improve stability, provide targeted delivery, and increase bioavailability.
Regenerative Medicine
Application Area
Show More (1)Key People
Charles E. Hinkle
Chief Financial Officer
Andrew Draganski, PhD
Vice President, Product Development
Michael Z. Rabin
Vice President, Strategy
Michael Burns, PhD
Vice President
Scott Grimshaw
Director Manufacturing & Engineering
News & Updates
Finalist of InnoVision’s 2023 competition
Zylö Therapeutics was a finalist for top technology applications in South Carolina, with the winner to be announced in October 2023.
Winner of Pitch Contest at SCBIO’s Annual Conference
Zylö Therapeutics won the pitch contest at SCBIO’s Annual Conference in Charleston, SC in 2023.
Winner of InnoVision's 2022 award
Zylö Therapeutics was awarded the top technology company in South Carolina in 2022.
Awarded by the NIH for the development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus in 2023.
$260,000 Phase 1 SBIR grant
Awarded by the NIH for the optimization of a nanoparticle-based topical PDE5i formulation for treatment of erectile dysfunction in 2022.
$600,000 Phase 1 SBIR grant
Awarded by the NIH for the development and optimization of a nitric oxide releasing microparticle-based topical treatment for onychomycosis in 2022.